Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Heron Therapeutics Inc (HRTX) Price & Performance

Direxion Daily CSI China Internet Bull 2X SharesTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Direxion Daily CSI China Internet Bull 2X Shares vs Heron Therapeutics Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $24.55, while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: Direxion Daily CSI China Internet Bull 2X Shares is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

CWEBHRTX
Sector
Leveraged / InverseHealth
52-Week High
$60.13$1.49
52-Week Low
$17.70$0.33
Market Cap
$63.41M
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Direxion Daily CSI China Internet Bull 2X Shares

CWEB trades at $25.53, up 1.67% today, with a bullish technical signal from moving averages. The stock shows strong momentum indicators but an overbought short-term RSI. A dividend of $0.09 is scheduled for June 2026, reflecting potential income return. Recent news highlights renewed interest in China growth stocks, which may benefit CWEB's positioning.

The outlook for CWEB is cautiously optimistic, driven by positive technical trends and sector sentiment. Key risks include reliance on China market dynamics and potential volatility. Investment opportunity lies in growth stock resurgence, but investors must weigh macroeconomic and regulatory uncertainties in the region.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Direxion Daily CSI China Internet Bull 2X Shares

CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.

Read more on CWEB

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX